Prenetics Global Ltd (PRE) - Cash Flow Conversion Efficiency

Latest as of September 2023: 0.016x

Based on the latest financial reports, Prenetics Global Ltd (PRE) has a cash flow conversion efficiency ratio of 0.016x as of September 2023. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($3.77 Million) by net assets ($228.78 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See how many days can Prenetics Global Ltd fund operations to measure how many days the company can operate on defensive assets alone.

Prenetics Global Ltd - Cash Flow Conversion Efficiency Trend (2001–2024)

This chart illustrates how Prenetics Global Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data.

Prenetics Global Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Prenetics Global Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Oceania Healthcare Ltd
AU:OCA
0.064x
UNID Company Ltd
KO:014830
-0.030x
Jasmine International Public Company Limited
BK:JAS
0.020x
B&G Foods Inc
NYSE:BGS
0.211x
Suzhou Shijing Environmental Technology Co.Ltd.
SHE:301030
N/A
Precious Shipping Public Company Limited
BK:PSL-R
0.038x
RPSG VENTURES LIMITED
NSE:RPSGVENT
0.209x
Medios AG
XETRA:ILM1
0.021x

Annual Cash Flow Conversion Efficiency for Prenetics Global Ltd (2001–2024)

The table below shows the annual cash flow conversion efficiency of Prenetics Global Ltd from 2001 to 2024. For the full company profile with market capitalisation and key ratios, see how much is Prenetics Global Ltd worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2024-12-31 $171.35 Million $-28.87 Million -0.169x -157.28%
2023-12-31 $210.16 Million $-13.76 Million -0.065x -209.86%
2022-12-31 $243.46 Million $14.51 Million 0.060x +278.14%
2021-12-31 $-400.89 Million $13.42 Million -0.033x +63.97%
2020-12-31 $31.01 Million $-2.88 Million -0.093x +16.88%
2019-12-31 $16.85 Million $-1.88 Million -0.112x -341.94%
2015-12-31 $6.90 Billion $318.81 Million 0.046x -61.52%
2014-12-31 $7.10 Billion $852.60 Million 0.120x -1.84%
2013-12-31 $6.77 Billion $827.27 Million 0.122x +22.28%
2012-12-31 $6.93 Billion $693.29 Million 0.100x +12.74%
2011-12-31 $6.47 Billion $573.63 Million 0.089x -47.90%
2010-12-31 $7.21 Billion $1.23 Billion 0.170x +18.48%
2009-12-31 $7.65 Billion $1.10 Billion 0.144x -47.94%
2008-12-31 $4.20 Billion $1.16 Billion 0.276x -2.82%
2007-12-31 $4.32 Billion $1.23 Billion 0.284x +118.64%
2006-12-31 $3.79 Billion $491.77 Million 0.130x -61.07%
2005-12-31 $3.09 Billion $1.03 Billion 0.334x -11.50%
2004-12-31 $3.35 Billion $1.26 Billion 0.377x -14.95%
2003-12-31 $2.59 Billion $1.15 Billion 0.443x +33.99%
2002-12-31 $2.08 Billion $687.24 Million 0.331x +59.00%
2001-12-31 $1.75 Billion $363.76 Million 0.208x --

About Prenetics Global Ltd

NASDAQ:PRE USA Diagnostics & Research
Market Cap
$312.57 Million
Market Cap Rank
#14708 Global
#3438 in USA
Share Price
$20.50
Change (1 day)
+3.25%
52-Week Range
$7.25 - $22.15
All Time High
$120.81
About

Prenetics Global Limited, a health sciences company, focuses on advancing consumer health in Hong Kong, the United States, and internationally. It sells health and wellness products under the IM8 brand name; and provides fulfillment and distribution services for sports nutrition products under the Europa brand. The company is also involved in the operation of CircleDNA, a consumer genetic testing… Read more